NASDAQ:SCNI Scinai Immunotherapeutics Q3 2026 Earnings Results & Report $0.50 +0.03 (+7.27%) As of 03:08 PM Eastern This is a fair market value price provided by Massive. Learn more. Scinai Immunotherapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of $0.3040 versus the -$8.50 consensus estimate, while revenue of $1.86 million topped the $495 thousand estimate by $1.36 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market Opens Scinai Immunotherapeutics EPS ResultsActual EPS$0.3040Consensus EPS -$8.50Beat/MissBeat by +$8.8040One Year Ago EPSN/AScinai Immunotherapeutics Revenue ResultsActual Revenue$1.86 millionExpected Revenue$495 thousandBeat/MissBeat by +$1.36 millionYoY Revenue GrowthN/AUpcoming EarningsScinai Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesEarnings HistoryCompany Profile Scinai Immunotherapeutics Q3 2026 Earnings FAQ Did Scinai Immunotherapeutics beat earnings estimates for Q3 2026? Scinai Immunotherapeutics (NASDAQ:SCNI) reported earnings of $0.3040 per share for Q3 2026, beating the consensus estimate of -$8.50. The report was announced on Monday, November 9, 2026. What was Scinai Immunotherapeutics' revenue for Q3 2026? Scinai Immunotherapeutics reported revenue of $1.86 million for Q3 2026, against a consensus estimate of $495 thousand. When is Scinai Immunotherapeutics' next earnings date? Scinai Immunotherapeutics' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scinai Immunotherapeutics on the company's earnings history page. Scinai Immunotherapeutics Earnings HeadlinesScinai's Nine-Month Revenue Jumps 167% As CDMO Orders Exceed $8 MlnNovember 5, 2026 | rttnews.comScinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business ExpandsNovember 5, 2026 | prnewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Scinai Immunotherapeutics Shares to Reverse Split on Thursday, November 19th (NASDAQ:SCNI)November 3, 2026 | americanbankingnews.comScinai Immunotherapeutics Ltd.: Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingOctober 20, 2026 | finanznachrichten.deScinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingOctober 20, 2026 | prnewswire.comSee More Scinai Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email. Email Address About Scinai ImmunotherapeuticsScinai Immunotherapeutics (NASDAQ:SCNI) Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration. The company has focused its development efforts on therapies for inflammatory skin conditions, including plaque psoriasis, with programs directed at interleukin-17A, a cytokine associated with inflammatory and autoimmune disorders. In addition to advancing its own product candidates, Scinai has indicated that its NanoAb platform may support partnerships and licensing opportunities for the development of other targeted immunotherapies. The company is headquartered in Israel and conducts its research and development activities through its proprietary platform and external collaborations.View Scinai Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
